The Board of Directors of CSPC Pharmaceutical Group Limited announced that the Group has entered into an exclusive license agreement with Madrigal Pharmaceuticals Inc. for the global development, manufacturing and commercialization of the Group's oral small molecule glucagon-like peptide-1 receptor agonist, SYH2086. Under the terms of the Agreement, the Group agreed to grant Madrigal an exclusive license to develop, manufacture and commercialize SYH2086 worldwide, while retaining the Group's right to develop and commercialize other orally administered small-molecule GLP-1 receptor agonist products in China. The Group is eligible to receive a total consideration of up to USD 2.075 billion, including an upfront payment of USD 120 million plus potential development, regulatory, and commercial milestone payments of up to USD 1.955 billion, and up to double-digit royalties based on the annual net sales of SYH2086.